ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare Gross Margin Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FGRHHYPOTHETICAL MODEL
Since ’99
+127%
Expense Ratio
0.45%
placeholder
Holdings
77
cap-weighted
Inception
Nov 2019
placeholder
Full Sharpe
0.25
Ann. Return (LS)
7.6%
Ann. Volatility
30.9%
Max Drawdown
-85.4%
Test Sharpe ’19–26
0.46
Test FF5 α (ann.)
19.4%
vs Fama-French 5
Test FF5 α t-stat
2.33
significant (|t| ≥ 2)
Monthly turnover
9%
of the long leg, per rebalance
Cumulative return (LS)
127%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.56
what this fund holds
Long leg ann. return
18.5%
buyable, long-only
Long-short Sharpe
0.25
requires shorting
Bottom bucket ann. return
10.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

77 of 77 · 100.0% of book
TickerCompanySectorMarket capWeight
1RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
13.68%
2NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
7.02%
3THC
TENET HEALTHCARE CORPHealthcare$16.79B
6.86%
4EXEL
EXELIXIS INCHealthcare$14.06B
5.74%
5ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
4.27%
6CYTK
CYTOKINETICS INCHealthcare$9.98B
4.08%
7CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
3.97%
8KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
3.89%
9PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
3.70%
10IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
3.67%
11IBRX
IMMUNITYBIO INCHealthcare$8.04B
3.29%
12DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
2.36%
13TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
2.15%
14CRSP
CRISPR THERAPEUTICS AGHealthcare$4.61B
1.88%
15TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
1.69%
16RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.56%
17ALMS
ALUMIS INCHealthcare$3.65B
1.49%
18NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
1.46%
19RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
1.41%
20IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
1.29%
21BEAM
BEAM THERAPEUTICS INCHealthcare$2.83B
1.16%
22CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
1.13%
23ATAI
ATAIBECKLEY INCHealthcare$2.66B
1.09%
24IMNM
IMMUNOME INCHealthcare$2.53B
1.03%
25NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.98%
26BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.96%
27NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.94%
28GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
0.85%
29RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.83%
30SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.83%
31ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.81%
32VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.76%
33STOK
STOKE THERAPEUTICS INCHealthcare$1.81B
0.74%
34IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.73%
35ZYME
ZYMEWORKS INCHealthcare$1.77B
0.72%
36TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.70%
37ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.69%
38VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.65%
39NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.65%
40MAZE
MAZE THERAPEUTICS INCHealthcare$1.56B
0.64%
41SEPN
SEPTERNA INCHealthcare$1.51B
0.61%
42XNCR
XENCOR INCHealthcare$1.30B
0.53%
43ABSI
ABSCI CORPHealthcare$1.29B
0.53%
44INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.52%
45WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.46%
46AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.42%
47BIOA
BIOAGE LABS INCHealthcare$1.01B
0.41%
48JANX
JANUX THERAPEUTICS INCHealthcare$992M
0.41%
49KURA
KURA ONCOLOGY INCHealthcare$964M
0.39%
50TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.36%
51STTK
SHATTUCK LABS INCHealthcare$577M
0.24%
52FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.23%
53ARVN
ARVINAS INCHealthcare$517M
0.21%
54XOMA
XOMA ROYALTY CORPHealthcare$504M
0.21%
55PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.19%
56CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.17%
57ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.16%
58STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.16%
59UPB
UPSTREAM BIO INCHealthcare$382M
0.16%
60LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.13%
61FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.12%
62TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.11%
63QTTB
Q32 BIO INCHealthcare$255M
0.10%
64SRZN
SURROZEN INCHealthcare$255M
0.10%
65RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.10%
66KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.09%
67AGEN
AGENUS INCHealthcare$209M
0.09%
68DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.08%
69KRRO
KORRO BIO INCHealthcare$177M
0.07%
70ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.07%
71VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.05%
72CUE
CUE BIOPHARMA INCHealthcare$126M
0.05%
73RLYB
RALLYBIO CORPHealthcare$87M
0.04%
74FRMM
FORUM MARKETS INCHealthcare$83M
0.03%
75ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.03%
76XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.02%
77MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $244.82B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

77 classified
Value
Blend
Growth
Large
Mid
Small
10%3
34%6
17%5
7%10
13%14
4%5
2%18
1%5
<1%1

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 83% toward Large, 52% toward Growth. +12% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt83% → Large
SmallLarge
Value ↔ growth tilt52% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 77 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 77 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.9 (95% CI 1.2-3.0)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
18.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.87x
within
parametric
2.08x
over
cornish fisher
2.08x
over · unreliable

The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 1.87 (pass) but Gaussian VaR gives 2.08 (fail). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-1.24
Sharpe, January 2003 – December 2005
January 1999July 2026
Median Sharpe
0.09
Dispersion
0.68
Best window
1.02

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.78.4%24.7%
3 yearsp.a.25.4%20.9%
5 yearsp.a.5.3%1.0%
10 yearsp.a.16.5%6.3%
Since inceptionp.a.14.1%3.0%
Calendar years
YearLong legLong-short
20267 mo25.8%8.0%
202552.0%48.1%
2024-7.3%1.2%
202317.8%15.4%
2022-33.3%-31.5%
2021-9.7%-34.0%
202083.8%62.3%
201971.1%44.7%
2018-5.7%-10.3%
201744.9%17.3%
2016-32.6%-29.3%
20152.4%-4.8%
201421.5%-5.3%
201365.4%14.3%
201240.7%23.7%
20114.8%-11.2%
201023.1%8.3%
200916.0%-12.1%
20080.9%67.5%
2007-11.6%-24.5%
2006-2.4%-1.4%
20058.4%-18.4%
20048.2%-16.8%
200328.7%-4.7%
2002-39.1%-31.3%
2001-14.3%-8.0%
200066.5%-1.0%
1999113.3%183.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FGRH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-11-19 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$244.82B

Methodology

The Foundry Healthcare Gross Margin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Gross Margin signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.